Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

In one, a North Carolina lab allegedly billed for unnecessary urine drug tests, and in the other a Californian women submitted fraudulent claims for respiratory pathogen testing.

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.